Guanylin: Physiology and What Research Reports

What Guanylin Is

Guanylin is a short, cysteine-rich peptide hormone that acts as an endogenous ligand for the transmembrane receptor guanylate cyclase-C (GC-C, gene GUCY2C). It belongs to a small family that also includes uroguanylin, a closely related peptide with overlapping but not identical distribution and potency. Both peptides are described in the physiology literature as regulators of intestinal electrolyte and fluid homeostasis, acting locally on the epithelium that lines the gut rather than as classical long-range circulating hormones (PMID 35158329).

The family is of interest partly because the same receptor is targeted by bacterial heat-stable enterotoxins, which mimic guanylin-type signalling and produce secretory diarrhoea — an observation that first drew attention to the endogenous ligands. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, diagnosis or treatment.

Where Guanylin Is Produced

Localisation work has placed guanylin production squarely in the intestinal epithelium. A mouse study using histochemical methods reported that guanylin and uroguanylin were produced by intestinal epithelial cells of both columnar and secretory lineage, indicating that expression is not restricted to a single specialised cell type (PMID 27246004). Comparative work in human and rat tissue examined the cellular localisation of guanylin and uroguanylin mRNAs in duodenal and colonic mucosa, describing region- and species-related patterns of expression along the gut (PMID 27044258).

Interest has also extended beyond the intestine. A 2023 review examined the role of uroguanylin in the regulation of ion transport in salivary glands, extending the guanylin family story to exocrine secretion outside the gut (PMID 37808412).

What Guanylin Does: The GC-C Pathway

The canonical mechanism is straightforward in outline. Guanylin binds GC-C on the apical membrane of enterocytes; the receptor's intracellular guanylyl cyclase domain generates cyclic GMP; cGMP-dependent signalling then activates apical chloride and bicarbonate channels, and anion movement draws water into the lumen. A review of this axis described guanylin and uroguanylin as a nexus in intestinal electrolyte and fluid homeostasis, linking luminal salt and water handling to epithelial peptide release (PMID 35158329).

Downstream detail is not uniform along the bowel. A 2025 murine pharmacology study reported differential, segment-specific signalling pathways for GC-C-activated anion secretion in the ileocolon, indicating that the same receptor can recruit different effector routes depending on intestinal region (PMID 41297905). Researchers have also described a barrier-related role: one study reported that a guanylin ligand protected the intestinal immune barrier by activating the guanylate cyclase-C signalling pathway (PMID 34920371).

What the Literature Reports

Inflammatory bowel disease

Expression of the pathway appears to change in disease. A 2015 clinical-tissue study reported that the guanylate cyclase-C signalling pathway was down-regulated in inflammatory bowel disease, a finding often discussed alongside the barrier and secretory functions attributed to the axis (PMID 25979109).

Stress and stool properties in mice

A 2020 mouse study examined social defeat stress and reported decreased colonic guanylin and uroguanylin expression together with altered, drier stool properties, connecting psychological stress models to the peptide family and to luminal water handling (PMID 33381053).

Adipose tissue and lipolysis

Work outside the gut has tested the peptides on fat cells. A 2016 study reported that guanylin and uroguanylin stimulated lipolysis in human visceral adipocytes, which supported the idea of a gut–adipose signalling arm for this family (PMID 27108812).

Liver and metabolic models

A 2023 study in obesity-associated non-alcoholic fatty liver disease models reported that uroguanylin prevented hepatic steatosis, mitochondrial dysfunction and fibrosis, extending the family's experimental reach into hepatic metabolism (PMID 37517791).

Colorectal cancer biology

Because GC-C expression is largely restricted to intestinal epithelium, the receptor has been discussed as a tissue-specific marker. A 2022 review described guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer (PMID 35920071).

Summary Table of Cited Findings

How Guanylin Is Studied

Methods in the cited literature fall into a few recurring groups: immunohistochemistry and in situ hybridisation to localise peptide and mRNA in mucosal tissue (PMID 27044258); expression profiling of GC-C pathway components in patient-derived tissue compared with controls (PMID 25979109); and ex vivo electrophysiology of mounted intestinal segments to measure anion secretion after receptor activation, an approach used in the murine ileocolon work that reported segment-specific signalling (PMID 41297905).

Species choice matters for interpretation. A 2024 study examined the evolutionary divergence of receptor guanylyl cyclase C and reported implications for preclinical models used to test receptor-directed therapeutics, a caution that applies when rodent GC-C findings are read across to human biology (PMID 38029963).

Guanylin in Research: What Studies Report

The verified literature summarised here is descriptive and mechanistic — localisation, expression changes and receptor signalling — rather than clinical safety reporting, and the cited papers did not present adverse-event tables for guanylin administration in humans. Because GC-C activation drives fluid movement into the intestinal lumen, the secretory physiology described in the reviewed work is the pharmacologically relevant consideration discussed by researchers (PMID 35158329). No dosing information is presented on this page because the verified sources cited here did not supply human dosing data.

Why the Term Comes Up

Readers usually encounter "guanylin" in three contexts: as a textbook endogenous ligand for GC-C in gut physiology; as background to GC-C-directed agents and to the receptor's discussion as a colorectal cancer target (PMID 35920071); and as a metabolic curiosity after reports that the peptides acted on visceral adipocytes and on hepatic outcomes in obesity models (PMID 27108812). Knowing which of those literatures a claim comes from is the most useful filter when reading about this peptide family.

References

• Guanylin and uroguanylin: a promising nexus in intestinal electrolyte and fluid homeostasis (Journal of Physiology and Pharmacology, 2021)
• Guanylin and uroguanylin are produced by mouse intestinal epithelial cells of columnar and secretory lineage (Histochemistry and Cell Biology, 2016)
• Cellular localization of guanylin and uroguanylin mRNAs in human and rat duodenal and colonic mucosa (Cell and Tissue Research, 2016)
• Guanylin ligand protects the intestinal immune barrier by activating the guanylate cyclase-C signaling pathway (Acta Histochemica, 2022)
• The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease (Scandinavian Journal of Gastroenterology, 2015)
• Decreased Colonic Guanylin/Uroguanylin Expression and Dried Stool Property in Mice With Social Defeat Stress (Frontiers in Physiology, 2020)
• Differential segment-specific signalling pathways for guanylate cyclase C-activated anion secretion in murine ileocolon (British Journal of Pharmacology, 2025)
• Guanylin and uroguanylin stimulate lipolysis in human visceral adipocytes (International Journal of Obesity, 2016)
• Uroguanylin prevents hepatic steatosis, mitochondrial dysfunction and fibrosis in obesity-associated NAFLD (Metabolism, 2023)
• The Role of Uroguanylin in Regulation of Ion Transport in Salivary Glands (Acta Stomatologica Croatica, 2023)
• The evolutionary divergence of receptor guanylyl cyclase C has implications for preclinical models for receptor-directed therapeutics (Journal of Biological Chemistry, 2024)
• Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer (Personalized Medicine, 2022)